RNA - CIK 0001599901
Avidity Biosciences, Inc. trades as RNA and has a market capitalization of $1.81 B, making it the #2174 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $18.75M, up 72.1% from the prior year and net income of -$684.63M. This page tracks Avidity Biosciences, Inc. through 547 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years Avidity Biosciences, Inc.'s revenue grew from $379.00K to $18.75M, a compound annual growth rate of 74.6%. Net profit margin compressed from -2959.4% to -3650.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| 15-12G | - | 2026-03-09 |
| Delisting notice | 25-NSE | 2026-02-27 |
| Insider trade | 4 | 2026-02-27 |
| Insider trade | 4 | 2026-02-27 |
| Insider trade | 4 | 2026-02-27 |
| Insider trade | 4 | 2026-02-27 |
| Insider trade | 4 | 2026-02-27 |
The largest companies sharing Avidity Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
Avidity Biosciences, Inc. (RNA) has a market capitalization of $1.81 B as of 2026-06-10, ranking #2174 among US-listed companies.
Avidity Biosciences, Inc. reported revenue of $18.75M for fiscal year 2025, an increase of 72.1% year over year.
In its latest fiscal year Avidity Biosciences, Inc. reported a net loss of $684.63M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.